Pharmacology and tolerability of a single dose of exenatide in adolescent patients with type 2 diabetes mellitus being treated with metformin: A randomized, placebo-controlled, single-blind, dose-escalation, crossover study

Clinical Therapeutics

Volumn 31, Issue 4, 2009, Pages 806-815

  Malloy, Jaret ^a   Capparelli, Edmund ^b   Gottschalk, Michael ^b   Guan, Xuesong ^a   Kothare, Prajakti ^c   Fineman, Mark ^a  

^a AMYLIN PHARMACEUTICALS INC   (United States)

^b UCSD MEDICAL CENTER   (United States)

^c ELI LILLY AND COMPANY   (United States)

Author keywords

adolescents; exenatide; incretin; type 2 diabetes mellitus

Indexed keywords

EXENDIN 4; GLUCAGON; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; INSULIN; METFORMIN; PLACEBO; SULFONYLUREA;

ADOLESCENT; AREA UNDER THE CURVE; ARTICLE; BODY MASS; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DEHYDRATION; DIABETES CONTROL; DIABETIC DIET; DIABETIC PATIENT; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GLUCAGON BLOOD LEVEL; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INSULIN BLOOD LEVEL; KETONURIA; KINESIOTHERAPY; MALE; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PHARYNGITIS; POSTPRANDIAL STATE; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SINGLE BLIND PROCEDURE; SINGLE DRUG DOSE; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; UPPER ABDOMINAL PAIN; VOMITING;

ADOLESCENT; AREA UNDER CURVE; BLOOD GLUCOSE; CHILD; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GLUCAGON; HUMANS; HYPOGLYCEMIC AGENTS; INJECTIONS, SUBCUTANEOUS; INSULIN; MALE; PEPTIDES; POSTPRANDIAL PERIOD; SINGLE-BLIND METHOD; VENOMS;

EID: 65549096266     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2009.04.005     Document Type: Article

References (23)

1. Pinhas-Hamiel O., and Zeitler P. The global spread of type 2 diabetes mellitus in children and adolescents. J Pediatr. 146 (2005) 693-700
2. American Diabetes Association. Type 2 diabetes in children and adolescents. Diabetes Care. 23 (2000) 381-389
3. Alberti G., Zimmet P., Shaw J., et al. Type 2 diabetes in the young: The evolving epidemic: The International Diabetes Federation Consensus Workshop. Diabetes Care. 27 (2004) 1798-1811
4. Fagot-Campagna A., Pettitt D.J., Engelgau M.M., et al. Type 2 diabetes among North American children and adolescents: An epidemiologic review and a public health perspective. J Pediatr. 136 (2000) 664-672
5. Bloomgarden Z.T. Type 2 diabetes in the young: The evolving epidemic. Diabetes Care. 27 (2004) 998-1010
6. Fagot-Campagna A., Narayan K.M., and Imperatore G. Type 2 diabetes in children. BMJ 322 (2001) 377-378
7. Olshansky S.J., Passaro D.J., Hershow R.C., et al. A potential decline in life expectancy in the United States in the 21st century. N Engl J Med. 352 (2005) 1138-1145
8. Pinhas-Hamiel O., and Zeitler P. Clinical presentation and treatment of type 2 diabetes in children. Pediatr Diabetes. 8 Suppl 9 (2007) 16-27
9. Dean H.J., and Sellers E.A. Comorbidities and microvascular complications of type 2 diabetes in children and adolescents. Pediatr Diabetes. 8 Suppl 9 (2007) 35-41
10. Hillier T.A., and Pedula K.L. Complications in young adults with early-onset type 2 diabetes: Losing the relative protection of youth. Diabetes Care. 26 (2003) 2999-3005
11. Kaufman F.R. Type 2 diabetes mellitus in children and youth: A new epidemic. J Pediatr Endocrinol Metab. 15 Suppl 2 (2002) 737-744
12. Bobo N., Evert A., Gallivan J., et al., the Diabetes in Children Adolescents Work Group of the National Diabetes Education Program. An update on type 2 diabetes in youth from the National Diabetes Education Program. Pediatrics. 114 (2004) 259-263
13. Libman I.M., and Arslanian S.A. Prevention and treatment of type 2 diabetes in youth. Horm Res. 67 (2007) 22-34
14. Kaufman F.R. Consequences of weight gain associated with insulin therapy in adolescents. Endocrinologist. 16 (2006) 155-162
15. ® exenatide injection [prescribing information] (2008), Amylin Pharmaceuticals, Inc, San Diego, Ca
16. Buse J.B., Henry R.R., Han J., et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care. 27 (2004) 2628-2635
17. DeFronzo R.A., Ratner R.E., Han J., et al. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care. 28 (2005) 1092-1100
18. Kendall D.M., Riddle M.C., Rosenstock J., et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care. 28 (2005) 1083-1091
19. Klonoff D.C., Buse J.B., Nielsen L.L., et al. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr Med Res Opin. 24 (2008) 275-286
20. Fineman M.S., Bicsak T.A., Shen L.Z., et al. Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes. Diabetes Care. 26 (2003) 2370-2377
21. Kolterman O.G., Kim D.D., Shen L., et al. Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus. Am J Health Syst Pharm. 62 (2005) 173-181
22. Nielsen L.L., Young A.A., and Parkes D.G. Pharmacology of ex-enatide (synthetic exendin-4): A potential therapeutic for improved glycemic control of type 2 diabetes. Regul Pept. 117 (2004) 77-78
23. Stonehouse A., Okerson T., Kendall D., and Maggs D. Emerging incretin based therapies for type 2 diabetes: Incretin mimetics and DPP-4 inhibitors. Curr Diabetes Rev. 3 (2008) 101-109